1School of Pharmacy, Sri Balaji Vidyapeeth, SBV Campus, Pillayarkuppam, Puducherry, India
2Faculty of Pharmaceutical Sciences, UCSI University, UCSI Heights, 56000Kuala Lumpur, Malaysia
3Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai-73, India
4School of Pharmacy, Dhanalakshmi Srinivasan University, Trichy-621112
The outbreak of SARS-COV-2 in 2019 triggered a pandemic scenario worldwide, claiming 6.4 million lives. Favipiravir (FAV) is an RdRp inhibitor, recommended as a treatment for SARS-CoV-2 infection, with a half-life of 2-5.5 hours, which is very short. Hence, to increase the half-life and bioavailability this study aimed.
Thus, the current study’s goal was to create Nanoparticles as favipiravir-loaded PLGA NPs.
The nanoprecipitation technique was employed to create the favipiravir-loaded nanoparticles.
The nanoparticles size was established to be 175.6 2 nm and an EE more than 70 0.5%. NPs had a PDI of 0.130 and an electro kinetic potential indicating homogeneity and stability of 17.1 mV.
DSC, XRD analyses revealed no interaction between FAV and the excipients. The Morphology and the surface of the particles were revealed to be spherical and smooth by SEM. A dissolution investigation revealed that FAV was released more slowly (24h) and drug loaded NPs were shown (32h).
Therefore, it could be an effective product for combating SARS-CoV-2 infection due to its high patient adherence.
SARS-COV-2, RNA-Dependent-RNA Polymerase, Favipiravir-Loaded PLGA, Polydispersity Index, Mucoadhesive Nature, In-vitro Solubilization
